Optic Neuritis

Summary Table

1. Pathophysiology

Retrobulbar neuritis is inflammation of the optic nerve at a segment located behind the globe. Because the inflamed portion of the nerve sits posterior to the optic disc, the optic disc looks completely normal on initial fundoscopy. This produces the classic teaching aphorism: the patient sees nothing and the examiner sees nothing. This finding directly distinguishes retrobulbar neuritis from papillitis, where the inflamed segment is at the optic nerve head and the disc appears swollen.

The dominant mechanism is T-cell mediated demyelination. Activated lymphocytes cross the blood-brain barrier, attack myelin sheaths, and create a conduction block along the optic nerve axons. This single process explains every cardinal feature seen in the vignette.

Vision loss results from impaired axonal signal transmission to the lateral geniculate nucleus and visual cortex. Pain with eye movement occurs because the inflamed optic nerve sheath shares fascial attachments with the superior rectus and medial rectus muscles; ocular movement physically tugs on the swollen, tender nerve. Dyschromatopsia with red desaturation reflects preferential dysfunction of small parvocellular fibers that mediate fine color discrimination, since these fibers are highly vulnerable to demyelinating injury. Relative afferent pupillary defect (RAPD) arises because the affected eye transmits a weaker afferent signal to the pretectal nucleus; on the swinging flashlight test, moving light from the healthy eye to the affected eye causes paradoxical pupil dilation.

Over the following weeks, demyelinated axons undergo secondary atrophy, producing temporal optic disc pallor by 4 to 6 weeks. The strong link with multiple sclerosis is grounded in the shared demyelinating mechanism. Optic neuritis is the presenting feature in roughly 20% of MS patients and occurs at some point in 50% to 70% of cases. Uhthoff phenomenon, transient visual blurring during exercise or hot showers, reflects heat-induced conduction failure in already demyelinated fibers and is a classic post-recovery feature.

2. Classification / Clinical Manifestation

Optic neuritis can also be classified by visual recovery pattern: typical demyelinating (good recovery, MS-associated), NMOSD-related (severe loss, poor recovery, aquaporin-4 antibody positive), and MOG-antibody disease (often bilateral, often steroid-responsive but relapsing).

3. Diagnostic Workup

Bedside evaluation begins with visual acuity, color plates, and the swinging flashlight test to confirm the RAPD. Fundoscopy is the best initial test to triage between retrobulbar neuritis (normal disc) and papillitis (swollen disc), since this finding alone distinguishes the two anatomic forms.

MRI of the brain and orbits with gadolinium contrast is the most accurate (gold standard) test. It demonstrates contrast enhancement of the affected optic nerve and, equally important, screens for demyelinating lesions in the periventricular white matter, juxtacortical regions, brainstem, and spinal cord that fulfill McDonald criteria for dissemination in space. The number of T2 lesions on the baseline MRI is the strongest predictor of conversion to clinically definite multiple sclerosis over the following 10 years; a normal baseline MRI gives roughly a 25% risk, while two or more lesions raise the risk to over 70%.

Visual evoked potentials reveal prolonged P100 latency and provide objective evidence of conduction delay even after vision recovers clinically, which is useful for documenting subclinical prior episodes. OCT quantifies retinal nerve fiber layer thinning and is increasingly used for longitudinal monitoring. Lumbar puncture is reserved for atypical presentations or to support an MS diagnosis when imaging is equivocal. Serologic testing for aquaporin-4 (NMOSD) and MOG antibodies is essential when the presentation is bilateral, severe, recurrent, or accompanied by transverse myelitis, because these conditions need different long-term immunotherapy.

4. Management & Treatment

The cornerstone of acute treatment, established by the Optic Neuritis Treatment Trial, is intravenous methylprednisolone 1 gram once daily for three days, followed by oral prednisone 1 mg/kg/day for 11 days and a 4-day taper. This regimen speeds the rate of visual recovery, although it does not change the final visual acuity at one year. Oral prednisone alone, at conventional doses, is contraindicated because the original trial showed it increases the recurrence rate of optic neuritis without improving final visual outcomes.

The next best step after the diagnosis is established at the bedside is to initiate IV corticosteroids and to obtain an MRI brain and orbits with contrast if not already done, both to confirm diagnosis and to risk-stratify for MS. When the MRI shows two or more demyelinating lesions, the patient should be referred to neurology for early disease-modifying therapy, since early treatment delays conversion to clinically definite multiple sclerosis.

For patients with contraindications to high-dose steroids (uncontrolled diabetes, active infection, peptic ulcer disease, first-trimester pregnancy), individualized risk-benefit assessment is needed. In pregnancy, IV methylprednisolone may still be used in the second and third trimesters when vision loss is severe and threatens function. Plasma exchange is reserved for steroid-refractory cases and is particularly considered when NMOSD or MOG-antibody disease is suspected.

Long-term management focuses on the underlying demyelinating disorder. Most patients regain near-normal visual acuity within 4 to 6 weeks, although subtle deficits in color vision, contrast sensitivity, and depth perception (Pulfrich phenomenon) may persist. Uhthoff phenomenon, transient visual blurring with elevated body temperature or exercise, can recur for years and is not by itself a sign of clinical relapse; it should not be confused with a new attack.

5. Differential Diagnosis & Distractors

6. Traps & High-Yield Pearls

The most common error is to anchor on papilledema or non-arteritic anterior ischemic optic neuropathy when a vignette describes acute monocular vision loss with an RAPD. The trap turns on three details: the patient's age, the presence of pain on eye movement, and the appearance of the optic disc. A young woman with painful eye movements and a normal fundus is retrobulbar neuritis until proven otherwise. An older adult with painless vision loss and a pale, swollen disc is anterior ischemic optic neuropathy; if it is accompanied by headache or jaw claudication, treat empirically for giant cell arteritis with high-dose steroids before biopsy results return.

A second classic gotcha is the management question that lists "oral prednisone" as a tempting choice. Remember the lesson from the Optic Neuritis Treatment Trial: standard-dose oral prednisone alone raises the rate of recurrence. The correct sequence is IV methylprednisolone first, then an oral taper.

A third trap is the recurrent or bilateral presentation. When a stem describes severe bilateral vision loss, longitudinally extensive transverse myelitis, or recurrent optic neuritis with poor recovery, do not lock in on multiple sclerosis. Think neuromyelitis optica spectrum disorder (aquaporin-4 antibody) or MOG-antibody disease, both of which require different long-term immunotherapy and may need plasma exchange acutely.

A fourth pitfall is missing toxic or nutritional optic neuropathy. When vision loss is bilateral, painless, gradual, and accompanied by central scotomas, look for ethambutol use in a patient on tuberculosis therapy, methanol exposure, or B12 deficiency. These patients do not need IV methylprednisolone; they need removal of the offending agent or replacement of the missing nutrient.

The core competency being tested is pattern recognition of the classic triad (acute monocular vision loss, painful eye movements, dyschromatopsia in a young woman with a normal fundus) combined with correct sequencing of the workup (bedside examination first, then MRI brain and orbits with contrast as the confirmatory test) and the right pharmacologic plan (IV methylprednisolone, never oral prednisone alone).